Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group

Equities researchers at The Goldman Sachs Group began coverage on shares of Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) in a research note issued on Monday, Marketbeat reports. The firm set a "buy" rating and a $37.00 price target on the stock. The Goldman Sachs Group's target price points to a potential upside of 69.72% from the stock's current price.

ELVN has been the topic of several other research reports. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Jones Trading dropped their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $39.60.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN traded down $1.29 during trading hours on Monday, hitting $21.80. The company's stock had a trading volume of 661,678 shares, compared to its average volume of 291,742. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03. The company has a market capitalization of $1.07 billion, a PE ratio of -11.35 and a beta of 0.79. The business's 50-day moving average is $18.45 and its two-hundred day moving average is $20.59.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, analysts predict that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Activity

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.34, for a total transaction of $135,606.78. Following the sale, the chief operating officer now owns 303,309 shares of the company's stock, valued at approximately $6,169,305.06. This represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the completion of the sale, the insider now directly owns 1,002,688 shares of the company's stock, valued at approximately $20,665,399.68. This trade represents a 1.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 88,611 shares of company stock worth $1,676,289. 25.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ELVN. Rhumbline Advisers boosted its holdings in Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock worth $1,033,000 after buying an additional 2,466 shares during the period. Jane Street Group LLC bought a new position in shares of Enliven Therapeutics in the first quarter worth $578,000. Goldman Sachs Group Inc. boosted its stake in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock valued at $4,167,000 after buying an additional 80,506 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock worth $428,000 after buying an additional 1,693 shares in the last quarter. Finally, Ally Bridge Group NY LLC grew its position in Enliven Therapeutics by 19.8% during the first quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company's stock worth $3,341,000 after buying an additional 28,064 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.